Tocilizumab-anoh is approved for multiple conditions, including rheumatoid arthritis and COVID-19, in intravenous and subcutaneous formulations. Phase 3 study confirmed biosimilarity between ...

On July 2, 2024, Fresenius Kabi (“Fresenius”) announced the immediate availability of TYENNE (tocilizumab-aazg), in a subcutaneous formulation, in the United States. TYENNE, a biosimilar to ACTEMRA ...

Treatment with SC vs IV tocilizumab led to higher long-term remission rates in GCA-associated aortitis, though imaging and glucocorticoid-sparing outcomes were similar.

Credit: Fresenius Kabi. Tyenne is indicated for treatment of moderately to severely active rheumatoid arthritis, giant cell arteritis, active polyarticular juvenile idiopathic arthritis, and active ...

The US Food and Drug Administration (FDA) has approved the biosimilar tocilizumab-aazg (Tyenne), Fresenius Kabi, the drug's manufacturer, announced today. This is the second tocilizumab biosimilar ...

Strengthens and expands U.S. biosimilars immunology portfolio with multi-indication arthritis treatment “Biosimilars continue to be a key growth driver for Organon, and this acquisition complements ...

Please provide your email address to receive an email when new articles are posted on . Subcutaneous and IV tocilizumab led to similar rates of remission and inflammatory markers in GCA-associated ...

Your doctor has recommended expanding your treatment plan for rheumatoid arthritis (RA) to include an interleukin 6 (IL-6) inhibitor — a biologic that’s often prescribed when conventional ...

Long-term treatment with tocilizumab was effective in patients with moderate-to-severe thyroid eye disease (TED) that was resistant to corticosteroids, with 58% of patients achieving clinical ...

Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity with Actemra. The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a ...